Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€47.08

€47.08

0.560%
0.26
0.560%
?
 
10:32 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Pfizer Inc. Stock

Pfizer Inc. gained 0.560% compared to yesterday.
Our community is currently high on Pfizer Inc. with 9 Buy predictions and 4 Sell predictions.
As a result the target price of €55.00 shows a slightly positive potential of 16.822% compared to the current price of €47.08 for Pfizer Inc..
For the coming years our community has positive and negative things to say abot the Pfizer Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Conscious of the environment" there were negative voices in the community.

Pros and Cons of Pfizer Inc. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pfizer Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. 0.560% -3.821% -11.073% 18.712% -8.106% 51.375% 75.854%
Eli Lilly Corp. 0.020% -2.194% -11.396% 29.813% 18.390% 187.409% 324.099%
Merck & Co. Inc. 0.580% 1.651% -8.200% 34.603% 26.653% 12.680% 62.213%
AbbVie Inc. 1.470% 1.504% -9.778% 42.137% 15.642% 133.322% 130.355%

Comments

Buy Pfizer Inc.
Show more

Buy Pfizer Inc.
Show more

Sell Pfizer Inc.
Show more

News

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15


Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR)

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematologyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology


Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a

PFIZER REPORTS SECOND-QUARTER 2022 RESULTShttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS


Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance